Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Matthias M. Gaida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1499-7772; OpenAlex author ID A5041359420. Sources: OpenAlex.

Their work

Papers
50 (first author 5, last author 10)
Trials
0
Grants
0
Labs led
3
Collaborators
209
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: none · 2014: none · 2015: 2 papers · 2016: 7 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 6 papers · 2021: 8 papers · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 50

  1. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  2. Aberrant Expression of A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) in Pancreatic Cancer Leads to Dichotomic Functions. Last author DOI 10.1002/mco2.70462↗
  3. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  4. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  5. Reprogramming Immunosuppressive Bone Marrow–Derived Cells via CD44 Targeting Impacts Pancreatic Cancer Metastasis Co-author DOI 10.1101/2025.08.13.670111↗
  6. PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3475↗
  7. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding. Last author DOI 10.1007/s00423-024-03355-3↗
  8. Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery. Co-author DOI 10.1038/s41598-024-70441-3↗
  9. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  10. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.05.036↗
  11. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  12. Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. Co-author DOI 10.1172/jci162054↗
  13. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.matbio.2022.11.002↗
  14. Imaging features of intraductal tubulopapillary neoplasm of the pancreas and its differentiation from conventional pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19517-6↗
  15. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  16. Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1672↗
  17. [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist]. First author DOI 10.1007/s00292-021-00949-2↗
  18. Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment? Co-author DOI 10.1016/j.ejrad.2021.109603↗
  19. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2021.02.011↗
  20. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003270↗
  21. Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids Co-author DOI 10.1101/2021.08.26.457743↗
  22. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
  23. Assessment of tissue perfusion of pancreatic cancer as potential imaging biomarker by means of Intravoxel incoherent motion MRI and CT perfusion: correlation w… Co-author DOI 10.1186/s40644-021-00382-x↗
  24. Epithelial-to-Mesenchymal Transition in Pancreatic Cancer is associated with Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging. Last author DOI 10.7150/jca.63633↗
  25. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.1002/ijc.32733↗
  26. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients. Co-author DOI 10.1053/j.gastro.2020.04.037↗
  27. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  28. Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers12061656↗
  29. Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer is Associated with Tumor Hypoxia. Last author DOI 10.3390/cancers13010089↗
  30. The Microarchitecture of Pancreatic Cancer as Measured by Diffusion-Weighted Magnetic Resonance Imaging Is Altered by T Cells with a Tumor Promoting Th17 Pheno… Last author DOI 10.3390/ijms21010346↗
  31. Why is pancreatic cancer so deadly? The pathologist's view. First author DOI 10.1002/path.5260↗
  32. Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer. Last author DOI 10.3390/cells8091104↗
  33. Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24312↗
  34. Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. Last author DOI 10.7150/jca.21803↗
  35. Changes in the microarchitecture of the pancreatic cancer stroma are linked to neutrophil-dependent reprogramming of stellate cells and reflected by diffusion-… Last author DOI 10.7150/thno.21089↗
  36. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12967-017-1227-3↗
  37. Differential Diagnosis of Autoimmune Pancreatitis From Pancreatic Cancer by Analysis of Serum Gelatinase Levels. Co-author DOI 10.1097/mpa.0000000000000576↗
  38. Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-15-0390↗
  39. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  40. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0511↗
  41. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.18632/oncotarget.10323↗
  42. Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Co-author DOI 10.18632/oncotarget.7206↗
  43. Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. First author DOI 10.7150/ijbs.14996↗
  44. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. First author DOI 10.1038/nm.3957↗
  45. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. Co-author DOI 10.15252/emmm.201404837↗
  46. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12253-011-9444-1↗
  47. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elasta… Last author DOI 10.1155/2012/720768↗
  48. Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. Co-author DOI 10.1371/journal.pone.0048503↗
  49. Identification of serum proteins involved in pancreatic cancer cachexia. Co-author DOI 10.1016/j.lfs.2010.11.011↗
  50. Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. Co-author DOI 10.1016/j.surg.2010.04.026↗

Closest collaborators

The 25 strongest of 209 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 22 shared papers, 2011–2025 · strength 2.36
  2. Philipp Mayer · 15 shared papers, 2018–2025 · strength 2.22
  3. Miriam Klauß · 10 shared papers, 2018–2024 · strength 1.37
  4. Oliver Strobel · 10 shared papers, 2011–2022 · strength 0.82
  5. Markus Wolfgang Büchler · 8 shared papers, 2011–2023 · strength 0.71
  6. Stefan Heinrich · 4 shared papers, 2020–2025 · strength 0.58
  7. Martin Loos · 3 shared papers, 2021–2024 · strength 0.55
  8. Thomas P. Hank · 4 shared papers, 2021–2022 · strength 0.55
  9. Laura DeLong Wood · 4 shared papers, 2019–2026 · strength 0.50
  10. Klaus Felix · 7 shared papers, 2011–2018 · strength 0.47
  11. Nathalia A. Giese · 8 shared papers, 2011–2021 · strength 0.44
  12. Helmut Friess · 2 shared papers, 2025–2026 · strength 0.43
  13. İhsan Ekin Demir · 2 shared papers, 2025–2026 · strength 0.43
  14. Guralp Onur Ceyhan · 2 shared papers, 2025–2026 · strength 0.43
  15. Ekaterina Khristenko · 3 shared papers, 2020–2022 · strength 0.41
  16. Jörg Kaiser · 3 shared papers, 2020–2022 · strength 0.36
  17. Marina Lesina · 2 shared papers, 2025–2026 · strength 0.35
  18. Roland Rad · 2 shared papers, 2025–2026 · strength 0.35
  19. Hana Algül · 2 shared papers, 2025–2026 · strength 0.35
  20. Bruno Sáinz · 2 shared papers, 2024–2025 · strength 0.32
  21. Christopher Heeschen · 2 shared papers, 2024–2025 · strength 0.32
  22. S. Perwez Hussain · 5 shared papers, 2015–2020 · strength 0.29
  23. Sven Máté Treffert · 1 shared paper, 2025 · strength 0.26
  24. Lisa-Marie Mehner · 1 shared paper, 2025 · strength 0.26
  25. Véronique Orian‐Rousseau · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.